Ventripoint Diagnostics Stock Today
| VPT Stock | CAD 0.13 0.01 7.14% |
Performance0 of 100
| Odds Of DistressOver 88
|
VentriPoint Diagnostics is selling for under 0.13 as of the 28th of November 2024; that is 7.14 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.13. VentriPoint Diagnostics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for VentriPoint Diagnostics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of August 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | Category Healthcare | Classification Health Care |
Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease primarily in Canada, the United States, and Europe. It also develops a suite of applications for various heart diseases and imaging modalities, including congenital heart diseases, left or right heart failure, and normal hearts. The company has 157.68 M outstanding shares of which 275 shares are at this time shorted by private and institutional investors with about 0.0 days to cover all short positions. More on VentriPoint Diagnostics
Moving together with VentriPoint Stock
Moving against VentriPoint Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
VentriPoint Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. VentriPoint Diagnostics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding VentriPoint Diagnostics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO | Hugh MacNaught | ||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, Health Care, Health Care Equipment & Supplies, Diagnostics & Research, Healthcare (View all Sectors) | ||||
VentriPoint Diagnostics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to VentriPoint Diagnostics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsVentriPoint Diagnostics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand VentriPoint Diagnostics' financial leverage. It provides some insight into what part of VentriPoint Diagnostics' total assets is financed by creditors.
| |||||
VentriPoint Diagnostics (VPT) is traded on TSX Venture Exchange in Canada and employs 11 people. VentriPoint Diagnostics is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 20.5 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate VentriPoint Diagnostics's market, we take the total number of its shares issued and multiply it by VentriPoint Diagnostics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. VentriPoint Diagnostics classifies itself under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 157.68 M outstanding shares of which 275 shares are at this time shorted by private and institutional investors with about 0.0 days to cover all short positions.
VentriPoint Diagnostics has accumulated about 713.21 K in cash with (3.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Check VentriPoint Diagnostics Probability Of Bankruptcy
Ownership AllocationVentriPoint Diagnostics shows a total of 157.68 Million outstanding shares. About 97.9 % of VentriPoint Diagnostics outstanding shares are held by general public with 2.1 (%) owned by insiders and only 0.0 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check VentriPoint Ownership Details
VentriPoint Diagnostics Risk Profiles
Although VentriPoint Diagnostics' alpha and beta are two of the key measurements used to evaluate VentriPoint Diagnostics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.71 | |||
| Standard Deviation | 5.94 | |||
| Variance | 35.3 | |||
| Risk Adjusted Performance | (0.05) |
VentriPoint Stock Against Markets
| VPT | 7.14 |
|
| Compare Correlations |
Be your own money manager
Our tools can tell you how much better you can do entering a position in VentriPoint Diagnostics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Headlines Timeline Now
Headlines TimelineStay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
| All Next | Launch Module |
VentriPoint Diagnostics Corporate Management
Elected by the shareholders, the VentriPoint Diagnostics' board of directors comprises two types of representatives: VentriPoint Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of VentriPoint. The board's role is to monitor VentriPoint Diagnostics' management team and ensure that shareholders' interests are well served. VentriPoint Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, VentriPoint Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| BASc ICDD | Ex CEO | Profile | |
| Jim Graba | Application Trainer | Profile | |
| CPA CMA | Chief Officer | Profile | |
| Hirotaka Katagiri | CTO Director | Profile | |
| Jimmy Jeon | Chief Officer | Profile |
Additional Tools for VentriPoint Stock Analysis
When running VentriPoint Diagnostics' price analysis, check to measure VentriPoint Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VentriPoint Diagnostics is operating at the current time. Most of VentriPoint Diagnostics' value examination focuses on studying past and present price action to predict the probability of VentriPoint Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VentriPoint Diagnostics' price. Additionally, you may evaluate how the addition of VentriPoint Diagnostics to your portfolios can decrease your overall portfolio volatility.